Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

New Data Augment the Treatment Paradigm in HR+/HER2– Breast Cancer

July 10th 2024

Panelists from an OncLive Peer Exchange detail updated data in the hormone receptor–positive HER2– breast cancer treatment landscape.

Dr Davis on the Investigation of Neratinib Plus Trastuzumab Deruxtecan in Advanced HER2+ Solid Tumors

July 10th 2024

Andrew Davis, MD, discusses an ongoing phase 1 trial combining neratinib and trastuzumab deruxtecan in metastatic HER2-positive solid tumors.

Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 9th 2024

Key opinion leaders discuss other clinical trials, including the EMERALD study, and targeted therapies for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in later lines of therapy.

Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291

July 9th 2024

Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- locally advanced or metastatic breast cancer and led to its FDA approval, emphasizing the improved progression-free survival observed in patients with PIK3CA, AKT1, and PTEN alterations.

Evolving Best Practices for ESR1 Testing

July 8th 2024

The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.

EMERALD Study Design and Results for Elacestrant

July 8th 2024

Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.

Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

July 8th 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

July 8th 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

July 8th 2024

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

July 8th 2024

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

July 5th 2024

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Murthy Highlights Second-Line Treatment Considerations in ER+/HER2– Metastatic Breast Cancer

July 4th 2024

Pooja Murthy, MD, discusses second-line treatments in ER+/HER2– metastatic breast cancer for patients following progression on endocrine therapy plus a CDK4/6 inhibitor.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 3rd 2024

The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.

Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway

July 2nd 2024

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

July 2nd 2024

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Dr Davis on the Potential For ADCs to Continue to Reshape Breast Cancer Treatment

July 2nd 2024

Andrew Davis, MD, discusses how antibody-drug conjugates could continue to reshape the breast cancer treatment paradigm.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Case Presentation 1: PIK3CA Mutation With ESR1 Mutations

July 1st 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.

Dynamics of ESR1 Alterations and Serial Liquid Biopsies

July 1st 2024

In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.